Q1 EPS Estimate for Unicycive Therapeutics Raised by Analyst

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at Noble Financial lifted their Q1 2026 earnings per share estimates for shares of Unicycive Therapeutics in a note issued to investors on Tuesday, March 31st. Noble Financial analyst R. Leboyer now expects that the company will post earnings per share of ($0.45) for the quarter, up from their previous forecast of ($0.47). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q2 2026 earnings at ($0.52) EPS, Q4 2026 earnings at $0.87 EPS and FY2026 earnings at $0.85 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.36).

Several other equities research analysts have also commented on UNCY. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Guggenheim dropped their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Westpark Capital assumed coverage on shares of Unicycive Therapeutics in a research report on Thursday, February 19th. They set a “buy” rating on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Unicycive Therapeutics Trading Down 2.7%

Shares of UNCY stock opened at $6.93 on Thursday. The company’s fifty day moving average price is $6.67 and its 200-day moving average price is $5.79. The stock has a market cap of $174.91 million, a PE ratio of -3.19 and a beta of 1.81. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $11.00.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Lazard Asset Management LLC bought a new stake in Unicycive Therapeutics in the 2nd quarter valued at $55,000. JPMorgan Chase & Co. boosted its holdings in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after purchasing an additional 21,525 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Unicycive Therapeutics during the third quarter valued at about $182,000. Quadrature Capital Ltd bought a new stake in shares of Unicycive Therapeutics in the fourth quarter worth about $226,000. Finally, State Street Corp increased its holdings in shares of Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after purchasing an additional 10,400 shares during the last quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Guggenheim retained a “Buy” rating while lowering its price target from $46 to $40 — the new PT still implies a very large upside vs. the current share price, which can support bullish sentiment if the company hits clinical milestones. Guggenheim price target cut to $40
• Positive Sentiment: Noble Financial nudged a number of near-term quarterly estimates higher — Q1 2026 from ($0.47) to ($0.45), Q2 2026 from ($0.54) to ($0.52), and Q3 2026 from $0.74 to $0.79 — suggesting modestly improving near-term operational expectations. MarketBeat: Noble Financial raises Q1–Q3 estimates
• Positive Sentiment: Retail interest has surged this week (reports say a ~150% spike in retail buzz), which can produce sharp, momentum-driven upside ahead of binary events such as drug-approval outcomes. This increases short-term volatility and the chance of rapid price moves. UNCY retail buzz explodes 150%
• Neutral Sentiment: Consensus estimates remain mixed: market consensus for the current full year is still negative (around -$0.23 EPS), which contrasts with some analysts’ multi-quarter positive numbers — creating uncertainty about the timing and sustainability of profitability. MarketBeat consensus data
• Negative Sentiment: Noble Financial lowered its FY2026 outlook (from $1.02 to $0.85) and reduced Q4 2026 estimates (from $1.11 to $0.87), which is a downgrade to longer-term earnings optimism and could weigh on the stock if investors focus on the reduced full-year trajectory. MarketBeat: Noble lowers FY/Q4 estimates

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.